



## **Novel Insights into Interstitial Lung Disease Diagnostics and Treatment**

Guest Editors:

**Dr. Jacobo Sellarés**

Interstitial Lung Disease Unit,  
Respiratory Department,  
Hospital Clinic de Barcelona  
(Barcelona), 08036 Barcelona,  
Spain

**Dr. Fernanda Hernandez**

Department of Respiratory  
Medicine, Respiratory Institute,  
Hospital Clinic Barcelona, 08036  
Barcelona, Spain

Deadline for manuscript  
submissions:

**closed (31 December 2021)**

### **Message from the Guest Editors**

Dear Colleagues,

In recent years, interstitial lung diseases (ILD) have presented an amazing development. The different international consensus have made it possible to clarify the different types of ILDs and optimal therapies, especially for idiopathic pulmonary fibrosis (IPF). Recent clinical trials have permitted the use of nintedanib and pirfenidone to reduce the progression of fibrotic disease. Additionally, the development of new techniques and the multidisciplinary discussion have been definitive in the progress of diagnosis accuracy. However, many areas are currently in development. The development of the “fibrotic pulmonary phenotype” definition in recent years and the beneficial effects of antifibrotics in this group has been one of the main recent advances in the field. This recent research has brought the ILD field into a novel and exciting moment. This Special Issue of *Journal of Respiration* aims to bring together current research and opinions on new concepts in diagnosis and treatment of interstitial lung diseases.





## Editor-in-Chief

**Prof. Dr. Cesar A. Moran**

Department of Pathology,  
University of Texas MD Anderson  
Cancer Center, Houston, TX, USA

## Message from the Editor-in-Chief

Over the last decade, the amount of information pertaining to thoracic structures has been unprecedented. The thorax is unique in terms of the different structures that involve the respiratory system—lungs, pleura, upper and lower respiratory tract—all located in the mediastinum that by itself represents a different compartment with its own wealth of conditions, and that also includes the Thymic gland. Therefore, we believe that the availability of a new open access journal, *JoR*, dedicated to highlighting and disseminating information related to the respiratory system is not only timely but is also absolutely necessary. As we can see, the information related to the respiratory systems is vast and there could not be anything more and better than to have a journal that is dedicated to the promotion, dissemination, and efficient publication of timely articles on the respiratory system including all its structures.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 52.3 days after submission; acceptance to publication is undertaken in 4.9 days (median values for papers published in this journal in the second half of 2025).

**Recognition of Reviewers:** APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.

## Contact Us

---